Introduction: Lifelong premature ejaculation (LPE) is characterized by persistently shorter intravaginal ejaculation latency time (IELT) than found acceptable by the patient or his partner. It has been postulated to be a neurobiological dysfunction with genetic vulnerability and is related to disturbances of central serotonin (5-hydroxytryptamine, 5-HT) neurotransmission and 5-HT receptor function. Aim: To investigate the relationship between the C–759T and G–697C polymorphisms of the 5-HT2C receptor and LPE. Methods: A prospective study was conducted in 106 Han Chinese men with LPE, characterized by IELT of less than 1 min, and 84 healthy controls with IELT of more than 3 min. All subjects were genotyped for the C–759T and G–697C polymorphisms located in the promoter region of the 5-HT2C receptor. The frequencies of genotypes and single nucleotide mutations were compared between the two groups. Results: Three genotypes were detected both in the men with LPE and in the control group: –759C/–697G, –759T/–697C, and –759C/ –697C. Genotype –759T/–697G was not detected. The frequency of genotype –759T/–697C was higher in patients with LPE than in the control group (30.2 vs. 11.9%, p < 0.05), whereas the frequency of genotype –759C/–697G was lower in patients with LPE than in the control group (66.0 vs. 83.3%, p < 0.05). No difference was found for genotype –759C/ –697C between the two groups. Mutations at –759T and –697C were more frequent in patients than in the control group (–759T: 30.2 vs. 13.3%, p < 0.05; –697C: 30.4 vs. 16.7%, p < 0.05, respectively). Conclusions: Our findings indicated that polymorphisms in the 5-HT2C receptor gene are associated with LPE, and men who carry the –759T or –697C genotype have increased odds of premature ejaculation. Further investigation in this field is necessary.

Keywords:
5-HT2C receptor, Polymorphism, Premature ejaculation, Serotonin, Intravaginal ejaculation latency time
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.